Lexaria Bioscience Corp. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
LEXX Nasdaq 2830 lexariabioscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lexaria Bioscience Corp.

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule - Jun 25th, 2026 7:10 am
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule - Jun 23rd, 2026 7:25 am
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand - Jun 17th, 2026 7:25 am
LEXX: Animal & Human GLP-1 Studies Continue - Jun 15th, 2026 3:42 am
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway - Jun 9th, 2026 7:25 am
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program - Jun 3rd, 2026 7:25 am
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 - May 19th, 2026 7:15 am
Lexaria Updates Progress on Human Study #7 - May 5th, 2026 7:10 am
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications - May 1st, 2026 7:25 am
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended - Apr 29th, 2026 7:10 am
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs - Apr 23rd, 2026 7:05 am
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales - Apr 21st, 2026 7:10 am
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property - Apr 15th, 2026 7:10 am
Lexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash Wisely - Apr 15th, 2026 4:25 am
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval - Apr 7th, 2026 7:10 am
Lexaria to Begin New Human Clinical Study in GLP-1 - Apr 1st, 2026 7:20 am
Lexaria's Robust Patent Portfolio Continues to Grow - Mar 26th, 2026 7:20 am
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry - Mar 24th, 2026 7:15 am
Lexaria Announces New R&D Plans for 2026 - Mar 4th, 2026 7:25 am
LEXX: First Quarter Results - Feb 10th, 2026 5:20 am